Ready to join our fight against cancer?
We are looking for an Senior Scientist with in vivo pharmacology experience.
The preclinical team is responsible for identifying and characterizing bispecific antibody (Biclonics®) lead candidates and elucidating their mechanism of action. Joining Merus means joining our pursuit to develop advanced therapies that address unmet needs in cancer treatment.
As (Senior) Scientist ‘in vivo pharmacology’ you are responsible for designing and organizing of a wide range in vivo studies for preclinical evaluation of Biclonics® candidates with immune-modulatory properties in the field of oncology.
Your main tasks and responsibilities are:
We are looking for a (Senior) Scientist ‘in vivo pharmacology’ with the following knowledge and expertise:
We offer a competitive salary and flexible working hours. Our talented international team works in an inspiring area of Utrecht (Utrecht Science Park) in a brand new state-of-the-art building. We also offer an excellent pension scheme, company bonus, and 30 days’ annual holiday based on a full-time position. We care about team spirit and organize several company events each year.
Working at Merus provides you with opportunities to grow and develop a career that offers both individual and company success. You will have the chance to make an impact within the oncology field by helping to develop bispecific antibody therapies (Biclonics®) to fight cancer. Merus’ headquarters are located in the Netherlands, with offices in the US and many collaborations around the world. As of 2016 we are listed on the NASDAQ stock exchange and over the last 10 years we have taken several candidate drugs into clinical trials. For more information, please visit www.merus.nl.
When hiring new employees, we look for people who will fit in well with the collaborative, rigorous, and entrepreneurial spirit of our company.
For more information about this role please contact Dr. Pieter Fokko van Loo via telephone number +31(0)30 – 253 8807.
This vacancy is a full time position.